TapewireFind a company

person · Reporting owner

SCHULMAN AMY W

Disclosed activity across 12 companies

Tapewire entity
16563
SEC CIK
0001438226

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132DirectorMay 20, 2026May 22, 2026
Elevance Health, Inc.ELV · Entity 2934DirectorMay 13, 2026May 15, 2026
FRACTYL HEALTH, INC.GUTS · Entity 6700DirectorJune 11, 2025June 13, 2025
Hudson Executive Investment Corp. IIHCII · Entity 130674DirectorApril 13, 2021April 14, 2021
Korsana Biosciences, Inc.CYCN · Entity 7698DirectorJune 16, 2020June 18, 2020
SQZ Biotechnologies CoSQZ · Entity 112267Director · 10% ownerJune 14, 2023June 15, 2023
Talkspace, Inc.HEC · Entity 22747DirectorJune 08, 2020June 08, 2020
X4 Pharmaceuticals, IncASNS · Entity 5638DirectorJune 05, 2018June 07, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date May 20, 2026 · Filed May 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect24,049 Reported balance After 2026-05-20 transaction · row 1
1 source row

Row 1 · 2026-05-20 · Grant · Acquired 838 · Balance 24,049

F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20Direct1,802 Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-20 · Grant · Acquired 1,802 · Balance 1,802

F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Elevance Health, Inc.

Report date May 13, 2026 · Filed May 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect781 Reported balance After 2026-05-13 transaction · row 1
1 source row

Row 1 · 2026-05-13 · Grant · Acquired 563 · Balance 781

F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

FRACTYL HEALTH, INC.

Report date June 11, 2025 · Filed June 13, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2035-06-10Direct22,500 Reported balance After 2025-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-06-11 · Grant · Acquired 22,500 · Balance 22,500

F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.

Hudson Executive Investment Corp. II

Report date April 13, 2021 · Filed April 14, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible securityDirect20,000 Reported balance After 2021-04-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-04-13 · Purchase · Acquired 20,000 · Balance 20,000

F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date

Korsana Biosciences, Inc.

Report date June 16, 2020 · Filed June 18, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2030-06-16Direct10,000 Reported balance After 2020-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-06-16 · Grant · Acquired 10,000 · Balance 10,000

F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SQZ Biotechnologies Co

Report date June 14, 2023 · Filed June 15, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13Direct39,875 Reported balance After 2023-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875

F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

Talkspace, Inc.

Report date June 08, 2020 · Filed June 08, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2020-06-08 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date.

X4 Pharmaceuticals, Inc

Report date June 05, 2018 · Filed June 07, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04Direct10,000 Reported balance After 2018-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blue Buffalo Pet Products, Inc.

Report date April 24, 2018 · Filed April 24, 2018

Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-04-24 transaction · row 1
1 source row

Row 1 · 2018-04-24 · Disposition to issuer · Disposed 14,819 · Balance 0

F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.

Section 16 reporting ended · disclosed 2025-09-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote2,825,500 Reported balance After 2025-09-11 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2025-09-11 · Purchase · Acquired 1,221,721 · Balance 2,825,500

F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.

F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote197,661 Reported balance After 2025-09-11 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2025-09-11 · Purchase · Acquired 85,468 · Balance 197,661

F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.

F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote909,090 Reported balance Holding disclosure · report date 2025-09-11 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 909,090

F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.

F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

IRONWOOD PHARMACEUTICALS INC

Report date April 01, 2019 · Filed April 03, 2019

Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect38,242 Reported balance After 2019-04-01 transaction · row 1
1 source row

Row 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 38,242

F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.

PFIZER INC

Report date December 31, 2013 · Filed January 03, 2014

Section 16 reporting ended · disclosed 2014-01-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible securityDirect5,075 Reported balance After 2013-12-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2013-12-31 · Grant · Acquired 59 · Balance 5,075

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2026 Filed May 22, 2026 20:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (Right to Buy) · Derivative 1,802 $0.00 Strike: $298.48 $0.00
Disclosure

SEC source: 0001178670-26-000041 · form4.xml · derivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,802

Underlying: Common Stock · 1,802 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:18 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 838 $0.00 $0.00
Disclosure

SEC source: 0001178670-26-000041 · form4.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,049

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
May 13, 2026 Filed May 14, 2026 20:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (Right to Buy) · Derivative 11,250 $0.00 Strike: $70.20 $0.00
Disclosure

SEC source: 0001178670-26-000017 · form4.xml · derivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2026-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The options exercised and held by the reporting person were due to expire on June 3, 2026.

Read SEC document
May 13, 2026 Filed May 14, 2026 20:17 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 11,250 $70.20 $789,750.00
Disclosure

SEC source: 0001178670-26-000017 · form4.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The options exercised and held by the reporting person were due to expire on June 3, 2026.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:16 UTC Elevance Health, Inc. ELV · Entity 2934 GrantCommon Stock 563 $0.00 $0.00
Disclosure

SEC source: 0001438226-26-000009 · wk-form4_1778876180.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 781

F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

Read SEC document
March 12, 2026 Filed Mar 23, 2026 20:10 UTC Elevance Health, Inc. ELV · Entity 2934 SaleCommon Stock 26 $287.50 $7,475.00
Disclosure

SEC source: 0001438226-26-000007 · wk-form4_1774296634.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218

Read SEC document
February 02, 2026 Filed Feb 3, 2026 21:42 UTC Elevance Health, Inc. ELV · Entity 2934 GrantCommon Stock 218 $0.00 $0.00
Disclosure

SEC source: 0001438226-26-000005 · wk-form4_1770154954.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218

F1 · shares: Phantom Stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.

F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of the annual meeting of shareholders that immediately precedes the Director's election date or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

Read SEC document
September 11, 2025 Filed Sep 11, 2025 20:59 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 85,468 $1.53 $130,766.04
Disclosure

SEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 2

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 197,661

F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.

F3 · ownership.nature: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
September 11, 2025 Filed Sep 11, 2025 20:59 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 1,221,721 $1.53 $1,869,233.13
Disclosure

SEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 1

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,825,500

F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.

F2 · ownership.nature: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:05 UTC FRACTYL HEALTH, INC. GUTS · Entity 6700 GrantStock Option · Derivative 22,500 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0000950170-25-086148 · ownership.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-10

F1 · derivative.exercise_date: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.

Read SEC document
May 08, 2025 Filed May 12, 2025 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 1,558 $0.00 Strike: $258.35 $0.00
Disclosure

SEC source: 0001735276-25-000061 · edgardoc.xml · derivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,558

Underlying: Common Stock · 1,558 shares

Expires 2035-05-08

F2 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
May 08, 2025 Filed May 12, 2025 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 775 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000061 · edgardoc.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,961

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
March 13, 2025 Filed Mar 14, 2025 20:16 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 2,750 $0.00 Strike: $131.21 $0.00
Disclosure

SEC source: 0001735276-25-000037 · edgardoc.xml · derivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,750 shares

Expires 2025-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The options exercised and held by the reporting person were due to expire on June 1, 2025.

F2 · derivative.exercise_date: The stock option was fully vested as of June 1, 2016.

Read SEC document
March 13, 2025 Filed Mar 14, 2025 20:16 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 2,750 $131.21 $360,827.50
Disclosure

SEC source: 0001735276-25-000037 · edgardoc.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The options exercised and held by the reporting person were due to expire on June 1, 2025.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 21:09 UTC FRACTYL HEALTH, INC. GUTS · Entity 6700 PurchaseCommon Stock 8,550 $1.17 $9,964.17
Disclosure

SEC source: 0000950170-25-040466 · ownership.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,550

F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from 1.165 to 1.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 277,536 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 9

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 24,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 3,967,234 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 8

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 353,718 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 980,829 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 7

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 87,448 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 14,020,475 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 6

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,250,061 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 909,090 $11.00 $9,999,990.00
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 5

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 909,090

F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 24,745 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 4

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 112,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 353,718 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 3

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,603,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 87,448 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 2

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,448

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 22:00 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 1,250,061 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 1

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,250,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 277,536 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 9

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 24,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries B Preferred Stock · Derivative 3,967,234 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 8

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 353,718 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 980,829 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 7

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 87,448 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 14,020,475 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 6

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,250,061 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 909,090 $11.00 $9,999,990.00
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 5

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 909,090

F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 24,745 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 4

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 112,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 353,718 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 3

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,603,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 87,448 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 2

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,448

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 1,250,061 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 1

Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner

Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner

Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner

Polaris Partners X, L.P. · CIK 0001910577 · 10% owner

Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner

SCHULMAN AMY W · CIK 0001438226 · 10% owner

Chee Brian · CIK 0001295675 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,250,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 25, 2024 Filed Jun 27, 2024 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 8,500 $0.00 Strike: $131.21 $0.00
Disclosure

SEC source: 0001735276-24-000072 · edgardoc.xml · derivative · entry 3

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,750

Underlying: Common Stock · 8,500 shares

Expires 2025-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024.

F2 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 1, 2016.

Read SEC document
June 25, 2024 Filed Jun 27, 2024 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 8,500 $240.00 $2,040,000.00
Disclosure

SEC source: 0001735276-24-000072 · edgardoc.xml · nonDerivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,436

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024.

Read SEC document
June 25, 2024 Filed Jun 27, 2024 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 8,500 $131.21 $1,115,285.00
Disclosure

SEC source: 0001735276-24-000072 · edgardoc.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024.

Read SEC document
May 29, 2024 Filed May 31, 2024 23:00 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $66.83 $0.00
Disclosure

SEC source: 0001735276-24-000058 · edgardoc.xml · derivative · entry 5

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2024-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.

F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of July 1, 2017.

Read SEC document
May 29, 2024 Filed May 31, 2024 23:00 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 63 $149.76 $9,434.88
Disclosure

SEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 4

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,436

F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.

Read SEC document
May 29, 2024 Filed May 31, 2024 23:00 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 11,516 $148.93 $1,715,077.88
Disclosure

SEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 3

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,499

F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 29, 2024 Filed May 31, 2024 23:00 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 10,121 $148.21 $1,500,033.41
Disclosure

SEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,015

F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 29, 2024 Filed May 31, 2024 23:00 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 30,000 $66.83 $2,004,900.00
Disclosure

SEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.

Read SEC document
May 16, 2024 Filed May 20, 2024 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 5,228 $0.00 Strike: $151.22 $0.00
Disclosure

SEC source: 0001735276-24-000047 · edgardoc.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,228

Underlying: Common Stock · 5,228 shares

Expires 2034-05-16

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 22:05 UTC FRACTYL HEALTH, INC. GUTS · Entity 6700 GrantStock Option · Derivative 45,000 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0000950170-24-011323 · ownership.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: The stock option vests in three annual installments beginning on February 1, 2025.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 20:46 UTC SQZ Biotechnologies Co SQZ · Entity 112267 GrantStock Option · Derivative 39,875 $0.00 Strike: $0.54 $0.00
Disclosure

SEC source: 0001209191-23-037386 · doc4.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,875

Underlying: Common Stock · 39,875 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:04 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 3,454 $0.00 Strike: $189.87 $0.00
Disclosure

SEC source: 0001735276-23-000063 · edgardoc.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,454

Underlying: Common Stock · 3,454 shares

Expires 2033-05-18

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:13 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionRestricted Stock Units · Derivative 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000019 · edgardoc.xml · derivative · entry 2

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 136 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date.

F2 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:13 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000019 · edgardoc.xml · nonDerivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 15, 2022 Filed Jun 16, 2022 21:01 UTC SQZ Biotechnologies Co SQZ · Entity 112267 GrantStock Option · Derivative 20,000 $0.00 Strike: $3.23 $0.00
Disclosure

SEC source: 0001209191-22-037493 · doc4.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

Read SEC document
May 18, 2022 Filed May 20, 2022 20:06 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 5,153 $0.00 Strike: $128.31 $0.00
Disclosure

SEC source: 0001735276-22-000051 · edgardoc.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,153

Underlying: Common Stock · 5,153 shares

Expires 2032-05-17

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 21:09 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantRestricted Stock Units · Derivative 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-22-000029 · edgardoc.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Underlying: Common Stock · 136 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.